21 results about "Choroidal neovascularization" patented technology

The invention belongs to the technical field of nano-drugs, and discloses a multifunctional nano-drug delivery system for treating neovascular eye diseases and a preparation method of the multifunctional nano-drug delivery system. The nano drug delivery system disclosed by the invention is a composite nano preparation which takes dendritic mesoporous silica nanoparticles as a carrier and co-loads cerium zirconium oxide nano enzyme and an anti-VEGF (vascular endothelial growth factor) drug, various active oxygen can be efficiently removed, oxygen is continuously released through catalytic decomposition of hydrogen peroxide, a retina hypoxia microenvironment is improved, and the retina hypoxia effect is improved. According to the present invention, the anti-VEGF drug delivery system can reduce the oxidative stress induced retinal pigment epithelial cell apoptosis rate, reduce the inflammatory reaction, and simultaneously achieve the slow release and the controlled release of the anti-VEGF drug, and the drug effect maintenance time can achieve more than 60 days, such that the multi-target synergistic treatment can be achieved through the synergistic regulation of the multiple pathological links such as oxygen deficit-oxidative stress-inflammation-angiogenesis, and the anti-VEGF drug delivery effect can be achieved. The choroidal neovascularization can be effectively inhibited by single intravitreal injection, and a new strategy of multi-target collaborative treatment is provided for neovascular macular degeneration and other eye diseases.

The invention relates to the technical field of medical image processing, in particular to an OCT image choroidal neovascularization segmentation method and system. According to the method, a TransUNet is taken as a reference network, and a heterogeneous feature alignment module, a curvature KAN attention guiding module and a deep and shallow double-path decoder are designed and embedded, so that a choroidal neovascularization segmentation model is constructed. Local features extracted by a convolutional neural network and global context features extracted by a visual extractor are integrated through a heterogeneous feature alignment module, and the network is promoted to comprehensively extract the features of the OCT image; a curvature KAN is used for guiding an attention module to optimize an attention mechanism so as to better acquire local geometric features of the image; the deep and shallow double-path decoder processes deep features and shallow features respectively by constructing two parallel decoding paths, thereby significantly enhancing the ability of the network to capture small target lesions. According to the method, the segmentation precision of the choroidal neovascularization of the OCT image is effectively improved.

The invention belongs to the technical field of biological medicines, and relates to application of an FGF2 inhibitor in preparation of a medicine for treating retina and choroidal neovascular diseases. An oxygen-induced retinopathy (OIR) mouse model and a novel small molecule compound are used for researching related mechanisms in retinopathy neovascularization, and the treatment effect of the small molecule compound is evaluated. Results show that the Refi-10 disclosed by the invention can be used for treating vascular retinopathy by inhibiting FGF2 targets, and a replacement or supplement method of VEGF (vascular endothelial growth factor) inhibiting drugs is provided.

The application discloses a choroid neovascularization image segmentation method based on a hybrid convolutional network, first, collecting fundus OCT scan images and labeling, and forming a data set by using the labeled images; a deep space-time separation hybrid convolutional neural network fusing an attention mechanism is constructed, two-dimensional feature extraction is carried out by using two-dimensional convolution, then the two-dimensional feature extraction is extended to three-dimensional, and then three-dimensional attention deep space-time separation convolution is carried out, and the two-dimensional feature and the three-dimensional feature are aligned and fused; then the hybrid neural network model constructed is trained by using the data set; finally, the trained hybrid neural network model is used to segment choroid neovascularization from the fundus OCT scan images, and a segmentation result is obtained. Through the space-time attention mechanism, local features of the choroid neovascularization image are better extracted, and by using the deep space-time separation convolution, a dimension reduction operation is carried out on the input feature map, so that the calculation parameters can be effectively reduced, thereby reducing the network calculation amount, and the channel attention can be more effectively calculated.

The invention belongs to the technical field of biological medicines, and particularly relates to application of emipril in preparation of a medicine for improving choroidal neovascularization related diseases. The invention aims to solve the problems of strong invasiveness and limited curative effect of the existing therapy. It is found that emipril can achieve differential regulation and control on a CD26 system in vivo, that is, the enzyme activity of CD26 in bone marrow is improved, the enzyme activity of CD26 in peripheral blood is reduced, the concentration gradient of stromal cell-derived factor-1 can be established between the bone marrow and the peripheral blood through differential regulation and control, and the concentration gradient of the stromal cell-derived factor-1 can be further improved. The bone marrow-derived cells are driven to homing to eye lesions and differentiate into repair cells, so that eye diseases are repaired or improved, meanwhile, the collection and migration of bone marrow-derived macrophages to CNV regions can be increased, and the anti-inflammatory effect is achieved. According to the application, an endogenous repair mechanism is activated through non-invasive administration, and a safer and more effective treatment method is provided for related eye diseases.

The present invention belongs to the field of tumor immunotherapy, and relates to a humanized anti-VEGF antibody Fab fragment. The present invention discloses nucleic acid sequences (including heavy / light chain variable regions) encoding said antibody fragment, and vectors, pharmaceutical compositions and kits containing said nucleic acid sequences. The anti-VEGF antibody Fab fragments disclosed in the present invention can specifically bind to VEGF with high affinity and block the binding of VEGF to the receptor VEGFR2, and also neutralize the proliferative effect of VEGF on HUVEC cells. Compared to the full-length antibody, antibodies in the form of Fab fragments have stronger penetrability and less toxic in terms of gastrointestinal perforation, hypertension and hemorrhage and do not stimulate the complement cascade reaction, thus reducing the risk of endophthalmitis and autoimmune inflammatory reactions. Thus it could be used in clinical treatment of ocular diseases characterized by choroidal neovascularization, including but not limited to age-related macular degeneration (AMD), diabetic macular edema (DME), retinal edema, degenerative myopia, choroidal neovascularization (CNV).

A method and system for detecting an advanced stage of age-related macular degeneration in a retina. Optical coherence tomography (OCT) imaging data for a retina is received. A presence of choroidal neovascularization (CNV) in the retina is detected, via a machine learning system, using the OCT imaging data. An output that indicates that the presence of CNV in the retina has been detected is generated.

The application discloses a dual-specific antibody with functions of inflammation microenvironment regulation and simultaneous inhibition of choroidal neovascularization, and a preparation method and application thereof. The dual-specific antibody is a single-chain antibody, comprises an IL1R, an IL-1 receptor complex auxiliary subunit IL-1RAcP fragment, and extracellular domains D2 (VEGFR2D2) and D3 (VEGFR2D3) of a tyrosine kinase transmembrane receptor VEGFR2, can simultaneously bind to IL-1 and VEGF, has functions of regulating an inflammation microenvironment and inhibiting choroidal neovascularization, and can more accurately treat fundus-related diseases represented by age-related macular degeneration.

The invention discloses application of dihydropyridine in preparation of a medicine for treating choroidal neovascularization, and belongs to the technical field of biological medicines.The proliferation, migration and lumen formation of human choroidal endothelial cells under the hypoxia condition are inhibited through dihydropyridine, and blood vessel leakage, area and volume of laser-induced choroidal neovascularization of mice are reduced; the formation of laser-induced choroidal neovascularization of mice is relieved through dihydropyridine, and the proliferation, migration and lumen formation of hypoxia-induced human choroidal endothelial cells can be down-regulated, so that the PHD has a treatment effect on CNV.

The invention relates to a construction method and application of an animal model with retina geographic atrophy (GA) accompanied by choroidal neovascularization (CNV) symptoms. According to the method, sodium iodate is injected at multiple points in the subretinal space of cynomolgus monkeys, so that the retina has typical and clinically close retinopathy GA and CNV symptoms, and the blank of animal models for preclinical evaluation of multi-target drugs for treating GA and CNV at present is filled.

Disclosed is a method of treating a patient with Geographic Atrophy or with wet Age-related Macular Degeneration or Choroidal Neovascularization. Also disclosed is a method of delaying the progression of vision loss in a patient with Geographic Atrophy or with wet Age-related Macular Degeneration or Choroidal Neovascularization. The methods comprise administering an effective amount of gildeuretinol acetate to the patient.

The invention relates to fluorinated modified aflibercept nano-particles and application thereof in eye drops, and belongs to the technical field of nano-drugs. The fluoridation modified aflibercept nano-particles disclosed by the invention are obtained by coupling a perfluoroalkane chain containing a maleimide group and reduced aflibercept. And due to the hydrophobic and oleophobic characteristics of the fluoroalkane chain and the chemical and biological inertness, the modified aflibercept can quickly cross an eye barrier after being dropped into eyes, and the content of VEGF in the eyes is reduced, so that the non-invasive and efficient treatment of CNV is realized. According to the invention, the administration route of aflibercept is innovated, the treatment of choroidal neovascularization can be realized through a non-invasive route in an eye drop administration mode, and the compliance of a patient is greatly improved.

The present invention discloses a method and system for segmenting choroidal neovascularization in optical coherence tomography images. By constructing a segmentation network based on UNet, two paths are provided during downsampling to respectively extract multi-scale global features and multi-scale global features with local semantic information and long-distance dependency information. The features extracted on the two paths are fused to output fused features of each scale, which can fully extract feature information. During upsampling, the fused features and upsampled features of the same scale are enhanced and then fused, which can further focus on the generation of lesion features during the upsampling process. In the upsampling process, lesion boundary information is used as supervisory information to enhance the expression of boundary information, thereby enabling refined segmentation and improving the segmentation effect.

This application discloses the fusion polypeptide AJ007 and its use, and belongs to the art of ophthalmic drugs. This fusion polypeptide AJ007 is formed by linking a TAT membrane-permeable peptide to the tip of a polypeptide HM-1 molecule that inhibits neovascularization. The fusion polypeptide AJ007 was used in the preparation of polypeptide eye drops, and by selecting the formulation of this application, the fusion polypeptide AJ007 was prepared as an eye drop. In the prevention or treatment of wet age-related macular degeneration, the method of administering eye drops effectively avoids various serious side effects and low patient tolerance problems associated with intravitreal injection in clinical practice, and has the advantage of non-invasive treatment. Furthermore, in a laser-induced mouse wAMD model, it showed extremely good efficacy in improving abnormal hyperplasia of choroidal neovascularization, and possesses high clinical therapeutic potential.

The present application relates to the technical field of medical image processing, and particularly relates to an OCT image choroidal neovascularization segmentation method and system. The present application takes TransUNet as a benchmark network, designs an embedded heterogeneous feature alignment module, a curvature KAN guided attention module and a deep-shallow dual-path decoder to build a choroidal neovascularization segmentation model. Through the heterogeneous feature alignment module, the local features extracted by the convolutional neural network and the global context features extracted by the visual extractor are integrated to enable the network to comprehensively extract the features of the OCT image. Through the curvature KAN guided attention module, the attention mechanism is optimized to better obtain the local geometric features of the image. The deep-shallow dual-path decoder processes deep features and shallow features through two parallel decoding paths respectively, thereby significantly enhancing the network's ability to capture small target lesions. The present application effectively improves the segmentation accuracy of the OCT image choroidal neovascularization.

Methods of treating choroidal neovascularization in a patient in need thereof are described herein. In some aspects, the method comprises inhibiting telomerase activity within a biological compartment of the patient. In some instances, inhibiting telomerase activity comprises disposing a telomerase inhibitor and / or disposing an antisense oligonucleotide within the biological compartment of the patient. In some embodiments, the biological compartment of the patient is the eye. Further, in some instances, the patient has neovascular age-related macular degeneration, diabetic retinopathy, retinopathy of prematurity (ROP), corneal neovascularization, and / or neovascular glaucoma.

The invention relates to the field of medicine application, and provides application of tanshinone IIA in preparation of a medicine for preventing and / or treating fundus neovascular diseases in subjects, in particular to wet age-related macular degeneration. In addition, the invention also provides application of the tanshinone IIA in preparation of a medicine for preventing and / or treating generation and leakage of choroidal neovascularization of eyes in a subject.

The application discloses application of SELE in treatment of wet age-related macular degeneration. The application research finds that SELE can significantly promote proliferation, migration and tube formation ability of vascular endothelial cells. SELE By inhibiting gene expression or activity, the application can significantly inhibit choroidal neovascularization in a wAMD mouse model, reduce abnormal vascular leakage, effectively reduce ocular inflammatory response, reduce inflammation-mediated vascular damage, target intervention of biological behavior of vascular endothelial cells, and block a key link of pathological angiogenesis. The application provides a novel molecular target for wAMD treatment and breaks the limitation of the existing anti-VEGF therapy.

The invention discloses an application of SELE in treatment of wet age-related macular degeneration. The research finds that the SELE can obviously promote the proliferation, migration and tube forming ability of vascular endothelial cells. By inhibiting SELE gene expression or activity, choroidal neovascularization in a wAMD mouse model can be significantly inhibited, and abnormal vascular leakage is reduced; meanwhile, the eye inflammatory response is effectively reduced, the inflammation-mediated vascular injury is relieved, the vascular endothelial cell biological behavior is intervened in a targeted manner, and the key link of pathological angiogenesis is blocked. The invention provides a brand new molecular target for wAMD treatment, and breaks through the limitation of the existing anti-VEGF therapy.

The invention discloses a method, a device and a system for constructing a screening prediction model of high myopia complications. The method comprises the following steps: acquiring conventional blood detection parameters; modeling by adopting different machine learning algorithms according to the conventional blood detection parameters; and evaluating the established model through a plurality of performance indexes. By the adoption of the technical scheme, screening of cataract, macular degeneration, choroidal neovascularization, glaucoma and retinal detachment complications of high-myopia patients is achieved.

The application provides an imino boronic ester structure-based ionizable lipidoid and a preparation method and application thereof in treating mouse choroidal neovascularization, has high mRNA delivery capacity, and is synthesized by a one-pot method of "Ax+By+Cz". The structure has dual sensitivity to slight acidity and ROS, and especially, the lipidoid lipidoid-A4B3C7 can be assembled into a complex with other lipid components and mRNA molecules, and has optimal mRNA delivery efficiency. In addition, in a mouse laser-induced choroidal neovascularization (CNV) model, by single intravitreal injection, an LNP-A4B3C7 co-encapsulated Cas9 mRNA (mCas9) and sgRNA (sgVEGFA) complex targeting a VEGFA gene (LNP-A4B3C7 / mCas9 / sgVEGFA complex) can successfully penetrate into the retinal RPE layer, effectively knock out the VEGFA gene in the RPE cell and significantly reduce the area of the neovascularization. The treatment effect is equivalent to that of the commercial fusion protein Aflibercept. These performances of the lipidoid make it have great development prospects in the field of biomedical materials, especially in the field of gene delivery and gene editing.